LONDON (Reuters) - London-listed pharmaceutical group Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion all-share deal to create a global specialist in medicines treating rare diseases with sales of $20 billion by 2020.
SHIRE (SHP.LO)went public with its proposal on Tuesday after Baxalta rejected the approach. Shire said it had offered to pay 0.1687 Shire ADR for each Baxalta share, implying a value of $45.23 per Baxalta share and a premium of 36 percent over Baxalta's stock price as on August 3.
Shares in Shire were down 8 percent on the news.
(Reporting by Paul Sandle; editing by Kate Holton)
